论文部分内容阅读
Objective Chimeric antigen receptor(CAR)targeting CD19 T-cell therapy has been reported to induce high response rate in patients with refractory and relapsed(R/R)Bcell acute lymphoblastic leukaemia(ALL)and lymphoma.